STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRBP
  4. [Form 4] Corbus Pharmaceuticals Holdings, Inc. Insider Trading Activity

Corbus Pharmaceuticals (CRBP) insider reports 30,029-share stock sale

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. insiders affiliated with Cormorant Asset Management reported selling 30,029 shares of common stock on 12/11/2025. The sale was coded as a disposition and executed in a series of open-market transactions at a weighted average price of $11.456 per share, with individual trade prices ranging from $11.20 to $12.15.

Following this transaction, the reporting persons indirectly beneficially owned 2,344,971 Corbus Pharmaceuticals shares. The filing states that all shares sold were held by Cormorant Global Healthcare Master Fund, LP and that each reporting person disclaims beneficial ownership beyond its or her pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, Chen Bihua
Role 10% Owner | 10% Owner | 10% Owner
Sold 30,029 shs ($344K)
Type Security Shares Price Value
Sale Common Stock 30,029 $11.456 $344K
Holdings After Transaction: Common Stock — 2,344,971 shares (Indirect, See Footnotes)
Footnotes (1)
  1. The reported price represents the weighted average sale price of Common Stock (the "shares") sold in a series of open market transactions on the transaction date at prices ranging from $11.20 to $12.15 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were sold by the Master Fund. Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as the general partner of the Master Fund. Bihua Chen serves as the managing member of Cormorant, GP LLC and the Master Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cormorant Asset Management, LP
(Last) (First) (Middle)
200 CLARENDON STREET
52ND FLOOR
(Street)
BOSTON MA 02116
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/11/2025 S 30,029 D $11.456(1) 2,344,971 I See Footnotes(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
Cormorant Asset Management, LP
(Last) (First) (Middle)
200 CLARENDON STREET
52ND FLOOR
(Street)
BOSTON MA 02116
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Cormorant Global Healthcare Master Fund, LP
(Last) (First) (Middle)
200 CLARENDON STREET
52ND FLOOR
(Street)
BOSTON MA 02116
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Chen Bihua
(Last) (First) (Middle)
C/O CORMORANT ASSET MANAGEMENT, LP
200 CLARENDON STREET, 52ND FLOOR
(Street)
BOSTON MA 02116
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The reported price represents the weighted average sale price of Common Stock (the "shares") sold in a series of open market transactions on the transaction date at prices ranging from $11.20 to $12.15 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were sold by the Master Fund.
2. Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as the general partner of the Master Fund. Bihua Chen serves as the managing member of Cormorant, GP LLC and the Master Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, Its General Partner By: /s/ Bihua Chen, Managing Member 12/15/2025
CORMORANT GLOBAL HEALTHCARE MASTER FUND, L.P. By: Cormorant Global Healthcare GP, LLC, Its General Partner By: /s/ Bihua Chen, Managing Member 12/15/2025
/s/ Bihua Chen 12/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CRBP report in this filing?

The filing reports that insiders affiliated with Cormorant Asset Management sold 30,029 shares of Corbus Pharmaceuticals Holdings, Inc. common stock on 12/11/2025, coded as a sale transaction.

At what price were the Corbus Pharmaceuticals (CRBP) shares sold?

The 30,029 Corbus Pharmaceuticals shares were sold at a $11.456 weighted average price per share, in open-market trades at prices ranging from $11.20 to $12.15 per share.

How many Corbus Pharmaceuticals shares do the reporting persons own after this sale?

After the reported sale, the filing shows the reporting persons indirectly beneficially owned 2,344,971 shares of Corbus Pharmaceuticals common stock.

Who executed the sale of Corbus Pharmaceuticals shares in this insider report?

The filing explains that all of the shares sold in this transaction were sold by Cormorant Global Healthcare Master Fund, LP, an investment fund managed by Cormorant Asset Management, LP.

Do the reporting persons claim full beneficial ownership of all reported CRBP shares?

No. The filing states that each of the reporting persons disclaims beneficial ownership of the reported shares except to the extent of its or her pecuniary interest in those shares.

What is the relationship between Cormorant Asset Management and the Master Fund holding CRBP shares?

The filing says Cormorant Asset Management, LP serves as the investment manager of Cormorant Global Healthcare Master Fund, LP, and that Cormorant Global Healthcare GP, LLC is the Master Fund’s general partner.